Louisbourg Investments Inc. Makes New Investment in Qiagen N.V. $QGEN

Louisbourg Investments Inc. purchased a new position in Qiagen N.V. (NYSE:QGEN) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 3,131 shares of the company’s stock, valued at approximately $150,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Blue Trust Inc. increased its stake in shares of Qiagen by 7.5% in the second quarter. Blue Trust Inc. now owns 14,532 shares of the company’s stock worth $698,000 after purchasing an additional 1,013 shares during the period. Callan Family Office LLC bought a new position in shares of Qiagen in the second quarter worth about $304,000. US Bancorp DE increased its stake in shares of Qiagen by 16.6% in the second quarter. US Bancorp DE now owns 66,901 shares of the company’s stock worth $3,215,000 after purchasing an additional 9,544 shares during the period. Vontobel Holding Ltd. bought a new position in shares of Qiagen in the second quarter worth about $1,594,000. Finally, OLD National Bancorp IN bought a new position in shares of Qiagen in the second quarter worth about $254,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on QGEN. Barclays set a $53.00 price objective on Qiagen and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Qiagen in a research note on Wednesday. Bank of America lifted their price objective on Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Thursday, June 26th. Cowen reiterated a “hold” rating on shares of Qiagen in a research note on Thursday, August 7th. Finally, Wall Street Zen cut Qiagen from a “buy” rating to a “hold” rating in a report on Saturday. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Qiagen presently has a consensus rating of “Hold” and an average price target of $49.40.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $46.93 on Friday. Qiagen N.V. has a 1-year low of $37.63 and a 1-year high of $51.88. The firm has a market capitalization of $10.43 billion, a PE ratio of 27.73, a PEG ratio of 2.46 and a beta of 0.66. The business’s 50 day moving average is $47.11 and its 200-day moving average is $45.50. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million for the quarter, compared to analyst estimates of $523.97 million. During the same quarter last year, the firm earned $0.55 EPS. Qiagen’s revenue for the quarter was up 7.7% compared to the same quarter last year. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Sell-side analysts predict that Qiagen N.V. will post 2.26 earnings per share for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.